1. Home
  2. Clinical Topics
  3. New treatment for peanut allergy in children
Clinical TopicsDrugs and DevicesHome CareImmune/Lymphatic SystemNewsPediatrics

New treatment for peanut allergy in children

By: Lydia L. Kim, Digital Content Editor

The U.S. Food and Drug Administration (FDA) recently approved Aimmune Therapeutics’ Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] for children suffering from peanut allergy.

Palforzia is intended to help “allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts” for children between the ages of 4 and 17, but these children are advised to continue to avoid peanuts in their daily diets.

Peter Marks, MD, PhD, the director of the FDA’s Center for Biologics Evaluation and Research comments on the approval: “Peanut allergy affects approximately 1 million children in the U.S. and only 1 out of 5 of these children will outgrow their allergy. Because there is no cure, allergic individuals must strictly avoid exposure to prevent severe and potentially life-threatening reactions…Even with strict avoidance, inadvertent exposures can and do occur. When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy.”

Please read more about the approval here.


Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.


Recent Posts